Blocking (Suppressor) Factors, Immune Complexes, and Extracorporeal Immunoadsorption in Tumor Immunity

  • Karl Erik Hellström
  • Ingegerd Hellström
  • Harry W. SnyderJr.
  • Joe P. Balint
  • Frank R. Jones
Part of the Contemporary Topics in Immunobiology book series (CTI, volume 15)


Some animal neoplasms, particularly many of those induced by chemical carcinogens, have tumor-specific transplantation antigens. These are detected by their ability to induce the rejection of tumors grafted onto properly immunized syngeneic hosts (Prehn and Main, 1957; Old and Boyse, 1964; Sjögren, 1965; K. E. Hellström and Brown, 1979), and the tumors expressing the antigens are commonly referred to as immunogenic. It is being debated whether “spontaneous” tumors, like most human tumors, have antigens that can be immunogenic in the native host (Klein and Klein, 1977; Hewitt et al., 1976; Hellström et al., 1983).


Tumor Antigen Acquire Immune Deficiency Syndrome Tumor Immunity Suppressor Factor Acquire Immune Deficiency Syndrome Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amlot, P., Pussel, B., Slaney, J. M., and Williams, B. D., 1978, Correlation between immune complexes and prognostic factors in Hodgkin’s disease, Clin. Exp. Immunol. 31: 166.PubMedGoogle Scholar
  2. Anderson, L. J., Jarrett, W. F. H., Jarrett, O., and Laird, H, M., 1971, Feline leukemia virus infection of kittens: Mortality associated with atrophy of the thymus and lymphoid depletion, J. Natl. Cancer Inst. 44: 339.Google Scholar
  3. Asherson, G. L., and Zembala, M., 1976, Suppressor T-cells in cell mediated immunity, Br. Med. Bull 32: 158.PubMedGoogle Scholar
  4. Baldwin, R. W., and Robins, R. A., 1977, Induction of tumor-immune responses and their interaction with the developing tumor, in: Contemporary Topics in Molecular Immunology, Vol. 6 ( R. R. Porter and G. L. Ada., eds.), pp. 177–207, Plenum Press, New York.Google Scholar
  5. Baldwin, R. W., Price, M. R., and Robins, R. A., 1972, Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumor-specific antigen-antibody complexes, Nature New Biol 238: 185.PubMedGoogle Scholar
  6. Baldwin, R. W., Price, M. R., and Robins, R. A., 1973, Inhibition of hepatoma-immune lymph node cell cytotoxicity by tumor-bearer serum, and solubilized hepatoma antigen, Int. J. Cancer 11: 527.PubMedGoogle Scholar
  7. Balint, J., Jr., 1982, Immune complexes with antiglobulin activity in sera of Moloney sarcoma bearing rats, Clin. Exp. Immunol 48: 70.PubMedGoogle Scholar
  8. Balint, J., Jr., and Jones, F. R., 1983, Perfusion of canine serum over Staphylococcus aureus Cowan I: Evidence for release of protein A and changes in specific antibody activity, Immunol Commun. 12: 573.PubMedGoogle Scholar
  9. Bansal, S. C., Bansal, B. R., Thomas, H. L., Siegel, P. D., Shoads, J. E., Cooper, D. R., Terman, D. S., and Mark, R., 1978, Ex vivo removal of serum IgG in a patient with colon carcinoma, Cancer 42: 1.PubMedGoogle Scholar
  10. Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., Daugnet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., Rozenbau, W., and Montagnier, 1983, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), Science 220: 868.PubMedGoogle Scholar
  11. Bensinger, W. I., Kinet, J. B., Hennen, G., Franckenne, F., Schaus, C., Saint-Remy, M., Hoyoux, P., and Mahieu, P., 1982, Plasma perfused over immobilized protein A for breast cancer, N. Engl. J. Med. 306: 935.Google Scholar
  12. Berke, G., 1980, Interaction of cytotoxic T lymphocytes and target cells, Prog. Allergy 27: 69.PubMedGoogle Scholar
  13. Brandeis, W. E., Nelson, L., Wang, Y., Good, R. A., and Day, N. K., 1978, Circulating immune complexes in sera of children with neuroblastoma: Correlation with stage of disease, J. Clin. Invest. 62: 1201.PubMedGoogle Scholar
  14. Catalona, W. T., Ratliff, T. L., and McCool, R. E., 1981, Gamma interferon induced by S. aureus protein A augments NK and ADCC, Nature 291: 77.PubMedGoogle Scholar
  15. Carpenter, J. L., and Holzworth, J., 1971, Treatment of leukemia in the cat, J. Am. Vet. Med. Assoc. 158: 1130.PubMedGoogle Scholar
  16. Carpentier, N. A., Fiere, D. M., Schuh, D., Ghislaine, T., Lange, T. A., and Lambert, P.-H., 1982, Circulating immune complexes and the prognosis of acute myeloid leukemia, N. Engl J.Med. 307: 1174.PubMedGoogle Scholar
  17. Cerrotini, J.-C., and Brunner, K. T., 1974. Cell-mediated cytotoxicity, allograft rejection and tumor immunity, Adv. Immunol. 18: 67.Google Scholar
  18. Cory, J., Nelson, K., Forstrom, J. W., Hellstrom, I., and Hellstrom, K. E., 1981, A T cell hybridoma suppressor factor which binds tumor antigen, in: Monoclonal Antibodies and T-Cell Hybridomas ( G. J. Hammerling, U. Hammerling, and J. F. Kearney, eds.), pp. 503–508, Elsevier/North-Holland, Amsterdam.Google Scholar
  19. Cotter, S. M., Essex, M., McLane, M. F., Grant, C. K., and Hardy, W. D., Jr., 1980, Chemotherapy and passive immunotherapy in naturally occurring feline mediastinal lymphoma, in: Feline Leukemia Virus ( W. D. Hardy, Jr., M. Essex, and A. J. McClelland, eds.), pp. 219–225, Elsevier/North-Holland, New York.Google Scholar
  20. Day, N. K., O’Reilly-Felice, C., Hardy, W. D., Jr., Good, R. A., and Withkin, S. S., 1980, Circulating immune complexes associated with naturally occurring lymphosarcoma in pet cats, J. Immunol. 125: 2363.PubMedGoogle Scholar
  21. Daynes, R. A., and Spellman, C. W., 1977, Evidence for the generation of suppressor cells by ultraviolet radiation, Cell. Immunol. 31: 182.PubMedGoogle Scholar
  22. Dorn, C. R., Taylor, D. O. N., and Hubbard, H. H., 1967, Epizootiologic characteristics of canine and feline leukemia and lymphosarcoma, Am. J. Vet. Res. 28: 993.PubMedGoogle Scholar
  23. Enker, W. E., and Jacobitz, J. L., 1980, In vivo splenic irradiation eradicates suppressor T cells causing the regression and inhibition of established tumor, Int. J. Cancer 25: 819.PubMedGoogle Scholar
  24. Essex, M., 1980, Feline leukemia and sarcoma viruses, in: Viral Oncology ( G. Klein, ed.), pp. 205–229, Raven Press, New York.Google Scholar
  25. Essex, M., Sliski, A., Cotter, S. M., Jakowski, R. M., and Hardy, W. D., Jr., 1975, Immunosurveillance of naturally occurring feline leukemia, Science 190: 790.PubMedGoogle Scholar
  26. Essex, M., Sliski, A., Cotter, S. M., and Hardy, W. D., Jr., 1976, The immune response to leukemia virus and tumor-associated antigen in cats, Cancer Res. 36: 640.PubMedGoogle Scholar
  27. Essex, M., McLane, M. F., Lee, T. H., Folk, L., Howe, C. W. S., Mullins, J. I., Cabradillo, C., and Frances, D. P., 1983, Antibodies to cell membrane antigens associated with T-cell leukemia virus in patients with AIDS, Science 220: 859.PubMedGoogle Scholar
  28. Fisher, M. S., and Kripke, M. L., 1982, Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet irradiated mice, Science 216: 1133.PubMedGoogle Scholar
  29. Forsgren, A., and Sjoquist, J., 1966, Protein A from S. aureus: I. Pseudo-immune reactions with human gamma globulin, J. Immunol. 97: 822.PubMedGoogle Scholar
  30. Forstrom, J. W., Nelson, K. A., Nepom, G. T., Hellstrom, I., and Hellstrom, K. E., 1983, Immunization to a syngeneic sarcoma by a monoclonal antiidiotype antibody, Nature 303: 627.PubMedGoogle Scholar
  31. Fujimoto, S., and Tada, T., 1978, I Region expression on cytotoxic and suppressor T cells against syngeneic tumors in the mouse, in: Cancer Immunotherapy and Its Immunological Basis ( Y. Yamamura, M. Kitagawa, and I. Azuma, eds.), pp. 11–20, University Park Press, Baltimore, Maryland.Google Scholar
  32. Gallo, R. C., Sarin, P. S., Gelmann, E. P., Robert-Guroff, M., Richardson, E., Kalyanaraman, V. S., Mann, D., Sidhu, G. D., Stahl, R. E., Zolla-Pazner, S., Liebowitch, I., and Popovic, M., 1983, Isolation of a human T cell leukemia virus in acquired immune deficiency syndrome (AIDS), Science 220: 865.PubMedGoogle Scholar
  33. Gelmann, E. P., Popovic, M., Blayney, D., Masur, H., Sidhu, G., Stahl, R. E., and Gallo, R. C., 1983, Proviral DNA of a retrovirus, human T-cell leukemia virus, in two patients with AIDS, Science 220: 862.PubMedGoogle Scholar
  34. Gershon, R. K., 1974, T cell control of antibody production, in: Contemporary Topics in Immunobiology, Vol. 3 ( M. D. Cooper and N. L. Warner, eds.), pp. 1–40. Plenum Press, New York.Google Scholar
  35. Gershon, R. K., Carter, R. L., and Kondo, K., 1967, On concomitant immunity in tumor-bearing hamsters, Nature 213: 674.PubMedGoogle Scholar
  36. Gershon, R. K., Mokyr, M. B., and Mitchell, M. S., 1974, Activation of suppressor T cells by tumor cells and specific antibody, Nature 250: 594.PubMedGoogle Scholar
  37. Gordon, B. R., Matus, R. E., Saal, S. D., MacEwen, E. G., Hurwitz, A., Stengel, K. H., and Rugin, A. L., 1983, Protein A independent tumoricidal responses in dogs after extracorporeal perfusion of plasma over Staphylococcus aureus, J. Natl. Cancer Inst. 70: 1127.PubMedGoogle Scholar
  38. Grant, C. K., DeBoer, D. J., Essex, M., Worley, M. B., and Higgins, J., 1977, Antibodies from healthy cats exposed to feline leukemia virus lyse feline lymphoma cells slowly with cat complement, J. Immunol. 119: 401.PubMedGoogle Scholar
  39. Gravell, M., London, W. T., Houff, S. A., Madden, D. L., Dalakas, M. C., Sever, J. L., Osborn, K. G., Maul, D. H., Hendrickson, R. V., Manx, P. A., Lerche, N. W., Prahalada, S., and Gardner, M. B., 1984, Transmission of simian acquired immunodeficiency syndrome (SAIDS) with blood or filtered plasma, Science 233: 74.Google Scholar
  40. Greene, M. L., 1980, The genetic and celluiar basis for regulation of the immune response to tumor antigens, in: Contemporary Topics in Immunobiology, Vol. 11 ( N. L. Warner, ed.), pp. 81–116, Plenum Press, New York.Google Scholar
  41. Greene, M. L., Dorf, M. E., Pierres, M., and Benacerraf, B., 1977, Reduction of syngeneic tumor growth by an anti-IJ-antiserum, Proc. Natl. Acad. Sci. USA 74: 5118.PubMedGoogle Scholar
  42. Groopman, J. D., Weinstein, W. M., Fahey, J. L., and Detels, R., 1983, The acquired immunodeficiency syndrome, Ann. Intern. Med. 99: 208.PubMedGoogle Scholar
  43. Gupta, R. K., Leitch, A. M., and Morton, D. L., 1983, Nature of antigens and antibodies in immune complexes isolated by Staphylococcal protein A from plasma of melanoma patients, Cell Immunol. Immunother. 16: 40.Google Scholar
  44. Gutterman, J. U., 1977, The Clq binding test for soluble immune complexes: Clinical correlations obtained in patients with cancer, J. Natl. Cancer Inst. 58: 1205.PubMedGoogle Scholar
  45. Hardy, W. D., Jr., 1980, Feline leukemia virus disease, in: Feline Leukemia Virus ( W. D. Hardy, Jr., M. Essex, and A.J. McClelland, eds.), pp. 3–31, Elsevier/North-Holland, New York.Google Scholar
  46. Hardy, W. D., Jr., Hirshaut, Y., and Hess, P., 1973, Detection of the feline leukemia virus and other mammalian oncornaviruses by immunofluorescence, in: Unifying Concepts of Leukemia ( R. M. Dutcher, and L. Chieco-Bianchi, eds.), pp. 778–799, Karger, Basel.Google Scholar
  47. Hardy, W. D., Jr., Hess, P. W., MacEwen, E. G., Hayes, A., Kassel, R. L., Day, N., and Old, L. J., 1975, Treatment of feline lymphosarcoma with feline blood constituents, in Comparative Leukemia Research ( J. Clemmesen and D. S. Yohn, eds.), pp. 518–521, Karger, Basel.Google Scholar
  48. Hardy, W. D., Jr., Hess, P. W., MacEwen, E. G., McClelland, A. J., Zuckerman, E. E., Essex, M., Cotter, S. M., and Jarrett, O., 1976, Biology of the feline leukemia virus in the natural environment, Cancer Res. 36: 582.PubMedGoogle Scholar
  49. Hardy, W. D., Jr., McClelland, A. J., MacEwen, E. G., Hess, P. W., Hayes, A. A., and Zuckerman, E. E., 1977, The epidemiology of feline leukemia virus (FeLV), Cancer 39: 1850.PubMedGoogle Scholar
  50. Harper, H. D., Sjoquist, J., Hardy, W. D., Jr., and Jones, F. R., 1985, Antitumor activity of protein A administered intravenously to pet cats with leukemia or lymphosarcoma, Cancer (in press).Google Scholar
  51. Hayami, M., Hellstrom, I., Hellstrom, K. E., and Yamanouchi, K., 1972, Cell-mediated destruction of Rous’ sacomas in Japanese quails, Int. J. Cancer 10: 507.PubMedGoogle Scholar
  52. Heimer, R., and Klein, G., 1976, Circulating immune complexes in sera of patients with Burkitt’s lymphoma and nasopharyngeal carcinoma, Int. J. Cancer 18: 310.PubMedGoogle Scholar
  53. Hellstrom, I., 1967, A colony inhibition (CI) technique for demonstration of tumor cell destruction by lymphoid cells in vitro, Int. J. Cancer 2: 65.PubMedGoogle Scholar
  54. Hellstrom, I., and Hellstrom, K. E., 1969, Studies in cellular immunity and its serum mediated inhibition in Moloney virus induced mouse sarcomas, Int. J. Cancer 4: 587.PubMedGoogle Scholar
  55. Hellstrom, I., and Hellstrom, K. E., 1970, Colony inhibition studies on blocking and non- blocking serum effects on cellular immunity to Moloney sarcomas, Int. J. Cancer 5: 195.PubMedGoogle Scholar
  56. Hellstrom, I., and Hellstrom, K. E., 1971, Colony inhibition and cytotoxicity assays, in: In Vitro Methods in Cell-Mediated Immunity ( B. R. Bloom and P. R. Glade, eds.), pp. 409–414, Academic Press, New York.Google Scholar
  57. Hellstrom, I., Hellstrom, K. E., and Pierce, G., 1968, In vitro studies of immune reactions against autochthonous and syngeneic mouse tumors induced by methylcholanthrene and plastic discs, Int. J. Cancer 3: 467.PubMedGoogle Scholar
  58. Hellstrom, I., Hellstrom, K. E., Evans, C. A., Heppner, G., Pierce, G. E., and Yang, J. P. S., 1969, Serum mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor specific antigens, Proc. Natl. Acad. Sci. USA 62: 362.PubMedGoogle Scholar
  59. Hellstrom, I., Hellstrom, K. E., and Sjogren, H. O., 1970, Serum mediated inhibition of cellular immunity to methylcholanthrene induced murine sarcomas, Cell. Immunol. 1: 18.PubMedGoogle Scholar
  60. Hellstrom, I., Hellstrom, K. E., and Bernstein, I. D., 1979, Tumor enhancing suppressor activator T cells in spleens and thymuses of tumor immune mice, Proc. Natl. Acad. Sci. USA 76: 52.Google Scholar
  61. Hellstrom, I., Hellstrojn, K. E., and Nelson, K., 1983, Antigen-specific suppressor (“blocking”) factors in tumor immunity, in: Biomembranes, Vol. 11: Pathological Membranes ( A. Nowotny, ed.), pp. 365–388, Plenum Press, New York.Google Scholar
  62. Hellstrom, K. E., and Brown, J. P., 1979, Tumor antigens, in: The Antigens ( M. Sela, ed.), pp. 1–82, Academic Press, New York.Google Scholar
  63. Hellstrom, K. E., and Hellstrom, I., 1970, Immunological enhancement as studied by cell culture techniques, Annu. Rev. Microbiol. 24: 373.PubMedGoogle Scholar
  64. Hellstrom, K. E., and Hellstrom, I., 1974, Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens, in: Advances in Immunology, Vol. 18 ( F. J. Dixon, ed.), pp. 209–277, Academic Press, New York.Google Scholar
  65. Hellstrom, K. E., and Hellstrom, I., 1978, Evidence that tumor antigens enhance tumor growth in vivo by interacting with a radiosensitive (suppressor?) cell population, Proc. Natl. Acad. Sci. USA 75: 436.PubMedGoogle Scholar
  66. Hellstrom, K. E., and Hellstrom, I., 1979, Enhancement of tumor outgrowth by tumor-associated blocking factors, Int. J. Cancer 23: 336.Google Scholar
  67. Hellstrom, K. E., and Hellstrom, I., 1981a, Cell-mediated suppression of tumor immunity has a nonspecific component. I. Evidence from transplantation tests, Int. J. Cancer 27: 481.PubMedGoogle Scholar
  68. Hellstrom, K. E., and Hellstrom, I., 1981b, Does perfusion with treated plasma cure cancer? N. Engl. J. Med. 305: 1215.PubMedGoogle Scholar
  69. Hellstrom, K. E., and Moiler, G., 1965, Immunological and immunogenetic aspects of tumor transplantation, Prog. Allergy 9: 158.Google Scholar
  70. Hellstrom, K. E., Hellstrom, I., and Nepom, J. T., 1977, Specific blocking factors-are they important? Biochim. Biophys. Acta 473: 121.PubMedGoogle Scholar
  71. Hellstrom, K. E., Hellstrom, I., Kant, J. A., and Tamerius, J. D., 1978, Regression and inhibition of sarcoma growth by interference with a radiosensitive T cell population, J. Exp. Med. 148: 799.PubMedGoogle Scholar
  72. Hendrickson, R. V., Maul, D. H., Osborn, K. G., Sever, J. L., Madden, D. L., Ellingsworth, L. R., Anderson, J. H., Lowenstine, L., and Gardner, M. D., 1983, Evidence of acquired immunodeficiency in Rhesus monkeys, Lancet 1: 388.Google Scholar
  73. Heppner, G. H., 1969, Studies on serum-mediated inhibition of cellular immunity to spontaneous mouse mammary tumor, Int. J. Cancer 4: 608.PubMedGoogle Scholar
  74. Hersey, P., Edwards, A., Adams, E., Hoister, J., Murray, E., Biggs, J., and Milton, G. W., 1976, Antibody-dependent, cell-mediated cytotoxicity against melanoma cells induced by plasmapheresis, Lancet 1: 825.PubMedGoogle Scholar
  75. Hewitt, H. B., Blake, E. R., and Walder, A. S., 1976, A critique of the evidence for active host defense against cancer based on personal studies of 27 tumors of spontaneous origin, Br. J. Cancer 33: 241.PubMedGoogle Scholar
  76. Hofken, H., Meredith, I. D., Robins, R. A., Baldwin, R. W., Davies, C. J., and Blarney, R. W., 1978, Immune complexes and prognosis of human breast cancer, Lancet 1: 672.Google Scholar
  77. Holohan, T. V., Phillips, T. M., and Bowles, C., 1982, Regression of canine mammary carcinoma after immunoadsorption therapy, Cancer Res. 42: 3663.PubMedGoogle Scholar
  78. Hunt, R. D., Blake, B. J., Chalifoux, L. V., Sehgal, P. K., King, N. W., and Letvin, N. L., 1983, Transmission of naturally occurring lymphoma in macaque monkeys, Proc. Natl Acad. Sci. USA 80: 5085.PubMedGoogle Scholar
  79. Isbister, W. H., Noonan, F. P., Halliday, W. J., and Clunie, G., 1975, Human thoracic duct cannulation: Manipulation of tumor-specific blocking factors in a patient with malignant melanoma, Cancer 35: 1465.PubMedGoogle Scholar
  80. Israel, L., Edelstein, R., Mannoni, P., and Radot, E., 1977, Plasmapheresis in patients with disseminated cancer. Clinical results and correlation with changes in serum proteins, Cancer 40: 3145.Google Scholar
  81. Jaffe, H. W., Choi, K., Thomas, P. A., Haverkos, H. W., Auerbach, D. M., Guinan, M. E., Rogers, M. F., Spira, T. J., Darrow, W. W., Kramer, M. A., Friedman, S. M., Monroe, J. M., Friedman-Kien, A. E., Laubenstein, L. J., Marmor, M., Safai, B., Dritz, S. K., Crispi, S. J., Fannin, S. L., Orkwis, J. P., Kelter, A., Rushing, W. R., Thacker, S. B., and Curran, J. W., 1983, National case-control study of Kaposi’s sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part I, Epidemiological results, Ann. Intern. Med. 99: 145.PubMedGoogle Scholar
  82. Jarrett, O., Laird, H. M., and Hay, D., 1973, Determinants of the host range of feline leukemia viruses, J. Gen. Virol. 20: 169.PubMedGoogle Scholar
  83. Jennette, J. C., and Feldman, J. D., 1977, Sequential quantitation of circulating immune complexes in syngeneic and allogeneic rats bearing Moloney sarcomas, J. Immunol. 118: 2269.PubMedGoogle Scholar
  84. Jones, F. R., 1978, In vivo studies of the mechanisms underlying enhancement and the reversal of tumor growth in mice employing X-irradiation and adoptive transfer of lymphoid cells, Ph.D. thesis, University of Washington, Seattle.Google Scholar
  85. Jones, F. R., Yoshida, L. H., Ladiges, W. C., and Kenney, M. A., 1980, Treatment of feline leukemia and reversal of FeLV by ex vivo removal of IgG: A preliminary report, Cancer 46: 675.PubMedGoogle Scholar
  86. Jones, F. R., Grant, C. K., and Snyder. H. W., Jr., 1984, Lymphosarcoma and persistent FeLV infection of pet cats: A system to study responses during extracorporeal treatments, J. Biol. Resp. Modif. 3: 286.Google Scholar
  87. Jones, J. F., Minnich, L. M., Lucas, D. O., Fulginiti, V. A., Ingham, Z., Langford, M.P., and Stanton, G. J., 1983, Serum interferon in Navajo children with severe combined immunodeficiency disease inhibits lymphoblastogenesis, J. Clin. Immunol. 3: 14.PubMedGoogle Scholar
  88. Kaliss, N., 1958, Immunological enhancement of tumor homografts in mice: A recent review, Cancer Res. 18: 992.PubMedGoogle Scholar
  89. Kali, M. A., Hellstrom, I., and Hellstrom, K. E., 1975, Different responses of lymphoid cells from tumor-bearing as compared to tumor-immunized mice when sensitized to tumor specific antigens in vitro, Proc. Natl. Acad. Sci. USA 72: 5086.Google Scholar
  90. Katz, D. H., 1977, Lymphocyte Differ entation, Recognition, and Regulation, Academic Press, New York.Google Scholar
  91. Kedbrat, S. S., Rasheed, S., Lutz, H., Gonda, M. A., Ruscetti, S., Gardner, M. B., and Prensky, W., 1983, Feline oncornavirus-associated cell membrane antigen: A viral and not a cellularly coded transformation-specific antigen of cat lymphomas, Virology 124: 445.Google Scholar
  92. Kessler, S. W., 1975, Rapid isolation of antigens from cells with a staphylococcal protein A antibody adsorbent: Parameters of the interaction of antibody-antigen complexes, J. Immunol. 115: 1617.PubMedGoogle Scholar
  93. Kiprov, D. D., and Morand, P., 1982, Lymphocyte subpopulations and mitogenic response studies in homosexuals with acquired immunodeficiency syndrome, Immunobiology 163: 337.Google Scholar
  94. Kiprov, D. D., Dan, P. C., and Morand, P., 1983, The effect of plasmapheresis and drug immunosuppression on T-cell subset as defined by monoclonal antibodies, J. Clin. Apheresis 1: 57.PubMedGoogle Scholar
  95. Kiprov, D. D., Lippert, R., Jones, F. R., Lagios, M. D., Balint, J. P., and Cohen, R. J., 1984, Extracorporeal perfusion of plasma over immobilized protein A in patient with Kaposi’s sarcoma and acquired immunodeficiency, J. Biol. Resp. Modif. 3: 341.Google Scholar
  96. Klein, G., and Klein, E., 1977, Rejectability of virus-induced tumors and nonrejectability of spontaneous tumors: A lesson in contrasts, Transplant. Proc. 9: 1095.PubMedGoogle Scholar
  97. Klein, G., Sjogren, H. O., Klein, E., and Hellstrom, K. E., 1960, Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host, Cancer Res. 20: 2561.Google Scholar
  98. Kripke, M. L., Lofgreen, J. S., Beard, J., Jessup, J. M., and Fisher, M. S., 1977, In vivo immune responses of mice during carcinogenesis by ultraviolet irradiation, J. Natl. Cancer Inst. 59: 1227.PubMedGoogle Scholar
  99. Letvin, N. L., Eaton, D. A., Aldrich, W. R., Sehgal, P. K., Blake, B. J., Schlossman, S. F., King, N. W., and Hunt, R. D., 1983, Acquired immunodeficiency syndrome in a colony of macaque monkeys, Proc. Natl. Acad. Sci. USA 80: 2718.PubMedGoogle Scholar
  100. McClelland, A. J., Hardy, W. D., Jr., and Zuckerman, E. E., 1980, Prognosis of healthy feline leukemia virus infected cats, in: Feline Leukemia Virus ( W. D. Hardy, Jr., M. Essex, and A. J. McClelland, eds.), pp. 121–126, Elsevier/North-Holland, New York.Google Scholar
  101. MacKintosh, F. R., Bennett, K., Schiff, S., Shields, J., and Hall, S. W., 1983, Treatment of advanced malignancy with plasma perfused over Staphylococcol protein A, West. J. Med. 139: 36.PubMedGoogle Scholar
  102. Mathes, L. E., Olsen, R. G., Hebebrand, L. C., Hoover, E. A., and Schaller, J. P., 1978, Abrogation of lymphocyte blastogenesis by a feline leukemia virus protein, Nature 274: 687.PubMedGoogle Scholar
  103. Messerschmidt, G. L., Bowles, C., and Alsaker, R., 1982a, Long-term followup of dogs with spontaneous mammary tumors treated with ex vivo plasma perfusion over Staphylococcus aureus Cowan I, Proc. Am. Assoc. Cancer Res. 23: 279.Google Scholar
  104. Messerschmidt, G., Bowles, C., Dean, D., Parker, M., Lester, R., Dowling, R., Holohan, T., Osborn, L., Schaff, B. F., McCormack, K., Corbitt, R., Phillips, T., Glasstein, E., and Deisseroth, A., 1982b, Phase II trial of S. aureus Cowan I immunoperfusion, Cancer Treatment Rep. 66: 2027.Google Scholar
  105. Mikulska, Z. B., Smith, C., and Alexander, P., 1966, Evidence for an immunological reaction of the host directed against its own actively growing primary tumor, J. Natl. Cancer Inst. 36: 29.PubMedGoogle Scholar
  106. Miller, W. J., Branda, R. F., Hurd, D. D., Wachsman, W., Nelson, N. L., and Jacob, H. D., 1982, Protein A adsorption of acute myelogenous leukemia serum induces in vitro blast lysis, Blood 59: 1344.PubMedGoogle Scholar
  107. Moller, E., 1965, Antagonistic effects of humoral isoantibodies on the in vitro cytotoxicity of immune lymphoid cells, J. Exp. Med. 122: 11.Google Scholar
  108. Mule, J. J., Hellstrom, I., and Hellstrom, K. E., 1982, Cell surface phenotypes of radiolabeled immune long-lived lymphocytes that selectively localize in syngeneic tumors, Am. J. Pathol. 107: 142.PubMedGoogle Scholar
  109. Naor, D., 1979, Suppressor cells: Permitters and promotors of malignancy? in: Advances in Cancer Research, Vol. 29 ( G. Klein and S. Weinhouse, eds.), pp. 45–125, Academic Press, New York.Google Scholar
  110. Nelson, K., 1975, Products of murine spleen cells that specifically modulate cell-mediated immunity to syngeneic tumor cells, Ph.D. thesis, University of Washington, Seattle.Google Scholar
  111. Nelson, K., Pollack, S. B., and Hellstrom, K. E., 1975a, Specific anti-tumor responses by cultured immune spleen cells. I In vitro culture method and initial characterization of factors which block immune cell-mediated cytotoxicity in vitro, Int. J. Cancer 15: 806.PubMedGoogle Scholar
  112. Nelson, K., Pollack, S. B., and Hellstrom, K. E., 1975a, Specific anti-tumor responses by cultured immune spleen cells. III. Further characterization of cells which synthesize factors with blocking and antiserum dependent cellular cytotoxic (ADC) activities, Int. J. Cancer 16: 539.PubMedGoogle Scholar
  113. Nelson, K., Pollack, S. B., and Hellstrom, K. E., 1975c, In vitro synthesis of tumor-specific factors with blocking and antibody-dependent cellular cytotoxicity, Int. J. Cancer 16: 932.PubMedGoogle Scholar
  114. Nelson, K., Cory, J., Hellstrom, I., and Hellstrom, K. E., 1980, A T-T hybridoma product specifically suppresses tumor immunity, Proc. Natl. Acad. Sci. USA 77:2866PubMedGoogle Scholar
  115. Nelson, K., Hellstrom, I., and Hellstrom, K. E., 1985, Tumor antigen-specific suppressor factors made by T cell hybridomas, in: T-Cell Hybridomas ( M. J. Taussig, ed.), pp. 129–138, CRC Press, Boca Raton, Florida.Google Scholar
  116. Nepom, J. T., 1977, Serum blocking factors: Purification and properties, Ph.D. thesis, University of Washington, Seattle.Google Scholar
  117. Nepom, J. T., Hellstrom, I., and Hellstrom, K. E., 1976, Purification of partial characterization of a tumor-specific blocking factor from sera of mice with growing chemically induced sarcomas, J. Immunol. 117: 1846.PubMedGoogle Scholar
  118. Nepom, J. T., Hellstrom, I., and Hellstrom, K. E., 1977, Antigen-specific purification of blocking factors from sera of mice with chemically induced tumors, Proc. Natl. Acad. Sci. USA 74: 4605.PubMedGoogle Scholar
  119. Nepom, J. T., Hellstrom, I., and Hellstrom, K. E., 1983, Suppressor mechanisms in tumor immunity, Experientia 39: 235.PubMedGoogle Scholar
  120. North, R. J., 1982, Cyclophosphamide facilitated adoptive immunotherapy of an established tumor depends on elimination of suppressor cells, J. Exp. Med. 155: 1063.PubMedGoogle Scholar
  121. Old, L. J., and Boyse, E., 1964, Immunology of experimental tumors, Annu. Rev. Med. 25: 167.Google Scholar
  122. Oldstone, M. B. A., Theofilopoulos, A. N., Gunven, P., and Klein, G., 1975, Immune complexes associated with neoplasia: Presence of Epstein-Barr virus antigen-antibody complexes in Burkitt’s lymphoma, J. Natl. Cancer Inst. 54: 223.PubMedGoogle Scholar
  123. Paranjpe, M. S., Boone, C. W., and Takeichi, N., 1976, Specific paralysis of the anti-tumor cellular immune response produced by growing tumors studied with a radioisotope footpad assay, Ann. N. Y. Acad. Sci. 276: 254.PubMedGoogle Scholar
  124. Perryman, L. E., Hoover, E. A., and Yohn, D. S., 1972, Immunologic reactivity of the cat: Immunosuppression in experimental feline leukemia, J. Natl. Cancer Inst. 49: 1357.PubMedGoogle Scholar
  125. Pinter, A., and Honnen, W. J., 1983, Topography of murine leukemia virus envelope protein: Characterization of transmembrane components, J. Virol 46: 1056.PubMedGoogle Scholar
  126. Prehn, R., and Main, D., 1957, Immunity to methylcholanthrene-induced sarcomas, J. Natl. Cancer Inst. 18: 768.Google Scholar
  127. Rao, V. S., Bennett, J. A., Shen, F. W., Gershon, R. K., and Mitchell, M. S., 1980, Antigen-antibody complexes generate Lyt-1 inducers of suppressor cells, J. Immunol. 125: 63.PubMedGoogle Scholar
  128. Ray, P. K., Idiculla, A., Rhoads, J. R., Jr., Bessa, E., Bassett, J. G., and Cooper, D. R., 1980a, Immunoadsorption of IgG molecules from the plasma of multiple myeloma and autoimmune hemolytic anemia patients, Plasma Ther. 1: 11.Google Scholar
  129. Ray, P. K., Idiculla, A., Bessa, E., Idiculla, A., and Rhoads, J. E., Jr., 1980b, Efficient removal of abnormal immunoglobulin G from the plasma of a multiple myeloma patient, Cancer 45: 2633.PubMedGoogle Scholar
  130. Rotter, V., and Trainin, N., 1975, Inhibition of tumor growth in syngeneic chimeric mice mediated by a depletion of suppressor T cells, Transplantation 20: 68.PubMedGoogle Scholar
  131. Sarma, P. S., and Log, T., 1971, Viral interference in feline leukemia-sarcoma complex, Virology 44: 352.PubMedGoogle Scholar
  132. Sarma, P. S., and Log, T., 1973, Subgroup classification of feline leukemia and sarcoma viruses by viral interferences and neutralization tests, Virology 54: 160.PubMedGoogle Scholar
  133. Schroff, R. W., Gottlieb, M. S., Prince, H. E., Chai, L. L., and Fahey, J. L., 1983, Immunological studies of homosexual men with immunodeficiency and Kaposi’s sarcoma, Clin. Immunol. Immunopathol. 27: 300.PubMedGoogle Scholar
  134. Sjogren, H. O., 1965, Transplantation methods as a tool for detection of tumor-specific antigens, Prog. Exp. Tumor Res. 6: 289.PubMedGoogle Scholar
  135. Sjogren, H. O., Hellstróm, I., Bansal, S. C., and Hellstróm, K. E., 1971, Suggestive evidence that the “blocking antibodies” of tumor-bearing individuals may be antigen-antibody complexes, Proc. Natl. Acad. Sci. USA 68: 1372.PubMedGoogle Scholar
  136. Sjoquist, J., and Stalenheim, G., 1969, Protein A from Staphylococcus aureus. IX. Complement-fixing activity of protein A-IgG complexes, J. Immunol. 103: 467.PubMedGoogle Scholar
  137. Smith, E. M., Johnson, H. M., and Blalock, J. E., 1983, Staphylococcus aureus protein A induces the production of alpha-interferon in human lymphocytes and alpha/beta-interferon in mouse spleen cells, J. Immunol. 130: 773.PubMedGoogle Scholar
  138. Snyder, H. W., Jr., Jones, F. R., Day, N. K., and Hardy, W. D., Jr., 1982, Isolation and characterization of circulating feline leukemia virus immune complexes removed from plasma of persistently infected pet cats by ex vivo immunoadsorption, J. Immunol. 128: 2726.PubMedGoogle Scholar
  139. Snyder, H. W., Jr., Singhal, M. C., Zuckerman, E. E., Jones, F. R., and Hardy, W. D., Jr., 1983, The feline oncornavirus-associated cell membrane antigen (FOCMA) is related to, but distinguishable from, FeLV-C gp70, Virology 131: 315.PubMedGoogle Scholar
  140. Snyder, H. W., Jr., Singhal, M. C., Hardy, W. D., Jr., and Jones, F. R., 1984, Clearance of feline leukemia virus from persistently infected pet cats treated by extracorporeal immunoadsorption is correlated with an enhanced antibody response to FeLV, J. Immunol. 132: 1538.PubMedGoogle Scholar
  141. Squire, R. A., and Bush, M., 1973, The therapy of canine and feline lymphosarcoma, in: Unifying Concepts of Leukemia (R. M. Dutcher and L. Chieco-Bianchi, eds.),pp. 189–197, Karger, Basel.Google Scholar
  142. Stalenheim, G., Gotze, O., Cooper, N. R., Sjoquist, J., and Muller-Eberhard, H. J., 1972, Consumption of human complement by complexes of IgG with protein A of Staphylococcus aureus, Immunochemistry 10: 501.Google Scholar
  143. Steele, G., Jr., Ankerst, J., and Sjogren, H. O., 1974, Alteration of in vitro anti-tumor activity of tumor bearer sera by adsorption with Staphylococcus aureus Cowan I, Int. J. Cancer 14: 83.PubMedGoogle Scholar
  144. Tamerius, J., Nepom, J., Hellstrôm, I., and Hellstrôm, K. E., 1976, Tumor-associated blocking factors: Isolation of sera of tumor-bearing mice, J. Immunol. 116: 724.PubMedGoogle Scholar
  145. Terman, D. S., Yamamota, Y., Mattioli, M., Cook, G., Tillquist, R., Henry, J., Poser, M. R.. and Daskal, Y., 1980a, Extensive necrosis of spontaneous canine mammary adenocarcinoma after extracorporeal perfusion over Staphylococcus aureus Cowan I, J. Immunol. 124: 795.PubMedGoogle Scholar
  146. Terman, D. S., Yamamoto, T., and Tillquist, R. L., 1980b, Tumoricidal response induced by cytosine arabinoside after plasma perfusion over protein A, Science 209: 1257.PubMedGoogle Scholar
  147. Terman, D. S., Young, J. B., and Shearer, W. T., 1981, Preliminary observations of the effects on breast adenocarcinoma of plasma perfusion over immobilized protein A, N. Engl. J. Med. 305: 1195.PubMedGoogle Scholar
  148. Theofilopoulos, A. N., and Dixon, F. J, 1980, Immune complexes in human disease, Am. J. Pathol. 100: 531.Google Scholar
  149. Theofilopoulos, A. N., Andrews, B. S., Urist, M. M., Morton, D. L., and Dixon, F. J. J., 1977, The nature of immune complexes in human cancer sera, J. Immunol. 199: 657.Google Scholar
  150. Tilkin, A. F., Schaaf, L. A., Fontaine, N., Van Acker, A., Boccadoro, M., and Urbain, J., 1981, Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor cells, Proc. Natl. Acad. Sci. USA 78: 1809.PubMedGoogle Scholar
  151. Trainen, Z., Wenicke, D., Unger-Waron, H., and Essex, M., 1983, Suppression of the humoral antibody response in natural retrovirus infections, Science 220: 858.Google Scholar
  152. Tucker, D. F., Begent, R. H., and Hogg, N. M., 1978, Characterization of immune complexes in serum by adsorption on Staphylococcal protein A: Model studies and application to sera of rats bearing Gross virus induced lymphoma, J. Immunol. 121: 1644.PubMedGoogle Scholar
  153. Umiel, T., and Trainin, N., 1974, Immunological enhancement of tumor growth by syngeneic thymus-derived lymphocytes, Transplantation 18: 244.PubMedGoogle Scholar
  154. Vaagc, J., 1972, Specific desensitization of resistance against a syngeneic methylchol-anthrene-induced sarcoma in CH3HF mice, Cancer Res. 32: 193.Google Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Karl Erik Hellström
    • 1
    • 2
    • 3
  • Ingegerd Hellström
    • 1
    • 2
    • 3
  • Harry W. SnyderJr.
    • 4
    • 5
  • Joe P. Balint
    • 4
    • 5
  • Frank R. Jones
    • 4
    • 5
  1. 1.OncogenSeattleUSA
  2. 2.Department of PathologyUniversity of WashingtonSeattleUSA
  3. 3.Department of Microbiology and ImmunologyUniversity of WashingtonSeattleUSA
  4. 4.Immune Response ProgramPacific Northwest Research FoundationSeattleUSA
  5. 5.Imré CorporationSeattleUSA

Personalised recommendations